cover-image

BerGenBio

NO: BGBIO

NOK2427.5m market cap

NOK27.62 last close

BerGenBio is a clinical stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune-evasive, drug-resistant and metastatic cancers. It focuses on AXL inhibitors bemcentinib (small molecule) and tilvestamab (mAb).

Investment summary

BerGenBio (BGBIO) has announced preliminary data for lead asset bemcentinib, an oral once daily highly selective AXL inhibitor for the treatment of severe COVID-19 infections requiring hospitalisation. In the Phase II ACCORD-2 and BGBC020 trials, treatment with bemcentinib led to numerically fewer deaths versus standard of care up to day 29. Preliminary analysis of the primary endpoint, time to clinical improvement of at least two points on the WHO nine-point ordinal scale, or live discharge from the hospital, was numerically in bemcentinib’s favour but not statistically significant in this small study with a diverse patient population and demographic. Detailed top-line data are expected in May. If favourable, we expect an additional global Phase III study will be required before emergency use authorisation. We value BGBIO at NOK4.72bn.

Y/E Dec
Revenue (NOKm)
EBITDA (NOKm)
PBT (NOKm)
EPS (öre)
P/E (x)
P/CF (x)
2019A 8.9 (203.6) (199.3) (343.4) N/A N/A
2020A 0.6 (260.4) (257.0) (343.1) N/A N/A
2021E 0.0 (305.1) (300.3) (342.6) N/A N/A
2022E 0.0 (319.6) (317.6) (361.6) N/A N/A
Industry outlook

Understanding the tumour microenvironment and why even with initial positive response to treatment, cancers often exhibit tumour proliferation, metastasis and treatment resistance is becoming an ever-more critical focus area. The role of AXL is becoming increasingly defined in tumorigenesis, propagation and treatment resistance.

Last updated on 05/05/2021
Register to receive research on BerGenBio as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (NOKm) 431.3
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (10.3) (17.4) (25.4)
Relative* (11.2) (22.7) (43.7)
52-week high/low NOK46.1/NOK25.6
*% relative to local index
Key management
Richard Godfrey CEO
Rune Skeie CFO